Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Sirnaomics Ltd. ( (HK:2257) ).
Sirnaomics Ltd. plans to terminate its share option scheme adopted in 2022 and introduce a new 2026 Share Option Scheme aligned with the latest Chapter 17 requirements of the Hong Kong listing rules. Options already granted under the existing scheme will remain valid and exercisable, and the board will not issue further options from the old plan ahead of a forthcoming shareholder vote.
The new 2026 Share Option Scheme is designed to offer a more flexible and compliant framework for retaining and incentivizing eligible participants through share-based rewards. Its adoption is subject to shareholder approval at an extraordinary general meeting and the Hong Kong Stock Exchange’s listing approval for any new shares to be issued, with a circular outlining full details to be sent to investors in due course.
More about Sirnaomics Ltd.
Sirnaomics Ltd., incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical sector, focusing on the development of RNA-based therapeutics. The company targets global healthcare markets and uses equity-based incentive schemes to attract and retain key talent as it advances its pipeline and commercial ambitions.
Average Trading Volume: 196,482
Technical Sentiment Signal: Sell
Current Market Cap: HK$787.8M
For a thorough assessment of 2257 stock, go to TipRanks’ Stock Analysis page.